Figure 10 (a) Structure of daptomycin, a lipodepsipeptide antibiotic produced by Streptomyces roseosporus, discovered by Eli Lilly and Co. in the late
1980s, acquired and developed by Cubist Pharmaceuticals in 1997 and FDA approved in 2003. (b) Structures of the arylomycin, actinocarbasin and
krisynomycin macrocyclic antibiotics that target type I bacterial signal peptidases. (c) Structures of antibiotic TA (also known as myxovirescin) and
globomycin macrolactone antibiotics that target type II bacterial signal peptidases.